Prophylactic Intravenous Hydration to Protect Renal Function From Intravascular Iodinated Contrast Material (AMACING): Long-term Results of a Prospective, Randomised, Controlled Trial
Estelle C Nijssen, Patty J Nelemans, Roger J Rennenberg, Vincent van Ommen, Joachim E Wildberger, Estelle C Nijssen, Patty J Nelemans, Roger J Rennenberg, Vincent van Ommen, Joachim E Wildberger
Abstract
Background: The aim of A MAastricht Contrast-Induced Nephropathy Guideline (AMACING) trial was to evaluate non-inferiority of no prophylaxis compared to guideline-recommended prophylaxis in preventing contrast induced nephropathy (CIN), and to explore the effect on long-term post-contrast adverse outcomes. The current paper presents the long-term results.
Methods: AMACING is a single-centre, randomised, parallel-group, open-label, phase 3, non-inferiority trial in patients with estimated glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m2 combined with risk factors, undergoing elective procedures requiring intravenous or intra-arterial iodinated contrast material. Exclusion criteria were eGFR < 30 mL/min/1.73 m2, dialysis, no referral for prophylaxis. The outcomes dialysis, mortality, and change in renal function at 1 year post-contrast were secondary outcomes of the trial. Subgroup analyses were performed based on pre-defined stratification risk factors. AMACING is registered with ClinicalTrials.gov: NCT02106234.
Findings: From 28,803 referrals, 1120 at-risk patients were identified. 660 consecutive patients agreed to participate and were randomly assigned (1:1) to no prophylaxis (n = 332) or standard prophylactic intravenous hydration (n = 328). Dialysis and mortality data were available for all patients. At 365 days post-contrast dialysis was recorded in two no prophylaxis (2/332, 0.60%), and two prophylaxis patients (2/328, 0.61%; p = 0.9909); mortality was recorded for 36/332 (10.84%) no prophylaxis, and 32/328 (9.76%) prophylaxis patients (p = 0.6490). The hazard ratio was 1.118 (no prophylaxis vs prophylaxis) for one-year risk of death (95% CI: 0.695 to 1.801, p = 0.6449). The differences in long-term changes in serum creatinine were small between groups, and gave no indication of a disadvantage for the no-prophylaxis group.
Interpretation: Assuming optimal contrast administration, not giving prophylaxis to elective patients with eGFR 30-59 mL/min/1.73 m2 is safe, even in the long-term.
Funding: Stichting de Weijerhorst.
Keywords: Clinical practice guidelines; Contrast-associated acute kidney injury; Contrast-induced nephropathy; Intravascular iodinated contrast administration; Prophylactic intravenous hydration.
Figures
References
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
- Ribichini F., Graziani M., Gambaro G. Early creatinine shifts predict contrast-induced nephropathy and persistent renal damage after angiography. Am J Med. 2010;123:755–763.
- Harjai K.J., Raizada A., Shenoy C. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol. 2008;101:812–819.
- Thomsen H.S., Morcos S.K. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003;76:513–518.
- LaBounty T.M., Shah M., Raman S.V., Lin F.Y., Berman D.S., Min J.K. Within-hospital and 30-day outcomes in 107994 patients undergoing invasive coronary angiography with different low-osmolar iodinated contrast media. Am J Cardiol. 2012;109:1594–1599.
- Katzberg R.W., Newhouse J.H. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010;256:21–28.
- James M.T., Samuel S.M., Manning M.A. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6:37–43.
- National Institute for Health and Care Excellence Acute kidney injury: prevention, detection and management. 2013. Available from: (accessed Sept 21, 2018)
- European Society of Urogenital Radiology ESUR guidelines on contrast media, version 9.0. September 2014. Available from: (accessed Sept 21, 2018)
- Committee on Drugs and Contrast Media, American College of Radiology (ACR) Manual on contrast media, version 10.3. Available from: (accessed Sept 21, 2018)
- Canadian Assocation of Radiologists Consensus guidelines for the prevention of contrast induced nephropathy. 2011. Available from: (accessed Sept 21, 2018)
- ASCI CCT & CMR Guideline Working Group ASCI 2010 contrast media guideline for cardiac imaging: a report of the Asian Society of Cardiovascular Imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group. Int J Cardiovasc Imaging. 2010;26:203–212. Available from: (accessed Sept 21, 2018)
- The Royal Australian and New Zealand College of Radiologists RANZCR iodinated contrast guidelines. Available from: (accessed Sept 21, 2018)
- Nederlandse Vereniging voor Radiologie Guideline safe use of contrast media. Available from: (accessed Sept 21, 2018)
- Van der Molen A.J., Reimer P., Dekers I.A. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018;28:2856–2869.
- Christiansen C. X-ray contrast media: an overview. Toxicology. 2005;209:185–187.
- Stacul F., van der Molen A.J., Reimer P. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21:2527–2541.
- Luo Y., Wang X., Ye Z. Remedial hydration reduces the incidence of contrast-induced nephropathy and short-term adverse events in patients with ST-segment elevation myocardial infarction: a single-center, randomized trial. Intern Med. 2014;53:2265–2272.
- Jurado-Roman A., Hernández-Hernández F., García-Tejada J. Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Am J Cardiol. 2015;115:1174–1178.
- Kooiman J., Sijpkens Y.W.J., van Buren M. Randomised trial of no hydration vs. sodium bicarbonate hydration in patients with chronic kidney disease undergoing acute computed tomography–pulmonary angiography. J Thromb Haemost. 2014;12:1658–1666.
- Martin-Moreno P.L., Varo N., Martinez-Anso E. Comparison of intravenous and oral hydration in the prevention of contrast-induced acute kidney injury in low-risk patients: a randomized trial. Nephron. 2015;131:51–58.
- Nijssen E.C., Rennenberg R.J., Nelemans P.J. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. The Lancet. 2017;389:1312–1322.
- Veligheids Management Systeem VMS veiligheidsprogramma: voorkomen van nierinsufficiëntie bij intravasculair gebruik van jodiumhoudende contrastmiddelen. September, 2009. (accessed Sept 21, 2018)
- Nijssen E.C., Nelemans P.J., Rennenberg R.J., van Ommen G.V., Wildberger J.E. Evaluation of safety guidelines on the use of iodinated contrast material conundrum continued. Invest Radiol. 2018;53:616–622.
- Bruce R.J., Djamali A., Shinki K. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. Am J Roentgenol. 2009;192:711–718.
- Hill N.R., Fatoba S.T., Oke J.L. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11
- Schwarz V., Heine G.H., Böhm M., Scheller B. Correspondence: hydration and contrast-induced kidney injury. The Lancet. 2017;390:452.
- Gurm H.S., Dixon S. Correspondence: hydration and contrast-induced kidney injury. The Lancet. 2017;390:452–453.
- Wyatt C.M., Camargo M., Coca S.G. Prophylactic hydration to prevent contrast-induced nephropathy: much ado about nothing? Kidney Int. 2017;92:4–6.
Source: PubMed